Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma

NIH Intramural Sequencing Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 20892, USA
BMC Genomics (Impact Factor: 3.99). 01/2012; 13(1). DOI: 10.1186/1471-2164-13-505


Metastasis is characterized by spreading of neoplastic cells to an organ other than where they originated and is the predominant cause of death among cancer patients. This holds true for melanoma, whose incidence is increasing more rapidly than any other cancer and once disseminated has few therapeutic options. Here we performed whole exome sequencing of two sets of matched normal and metastatic tumor DNAs.

Using stringent criteria, we evaluated the similarities and differences between the lesions. We find that in both cases, 96% of the single nucleotide variants are shared between the two metastases indicating that clonal populations gave rise to the distant metastases. Analysis of copy number variation patterns of both metastatic sets revealed a trend similar to that seen with our single nucleotide variants. Analysis of pathway enrichment on tumor sets shows commonly mutated pathways enriched between individual sets of metastases and all metastases combined.

These data provide a proof-of-concept suggesting that individual metastases may have sufficient similarity for successful targeting of driver mutations.

Download full-text


Available from: Jared Gartner, Mar 24, 2014
18 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite the rapidly decreasing cost and increasing throughput of next-generation sequencing technologies, deep targeted resequencing has maintained its importance in the sensitive detection of mutations by focusing only on targets of biomedical or clinical relevance. In this chapter, we review current as well as emerging technologies that enable the capture of specific elements from a sample. In particular, we focus on targeted resequencing in cancer research. To date, the cancer research community has sequenced over 2,500 cancer samples from 17 different tissue types by whole-exome targeted resequencing. In addition, clinically relevant targets such as known cancer genes and cancer-associated miRNAs and viruses have been sequenced selectively by targeted next-generation sequencing technologies. We expect that the use of targeted resequencing in cancer research will soon become a standard research and analysis method, and in turn further technological developments that allow for the improved extraction of genetic components will be rapidly adopted.
    Next Generation Sequencing in Cancer Research, 01/2013: pages 137-163; , ISBN: 978-1-4614-7644-3
  • [Show abstract] [Hide abstract]
    ABSTRACT: Melanoma progression is typically depicted as a linear and stepwise process in which metastasis occurs relatively late in disease progression. Significant evidence suggests that in a subset of melanomas, progression is much more complex and less linear in nature. Epidemiologic and experimental observations in melanoma metastasis are reviewed here and are incorporated into a comprehensive model for melanoma metastasis, which takes into account the varied natural history of melanoma formation and progression.Oncogene advance online publication, 3 June 2013; doi:10.1038/onc.2013.194.
    Oncogene 06/2013; 33(19). DOI:10.1038/onc.2013.194 · 8.46 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Adoptive T-cell therapy (ACT) is a potent and flexible cancer treatment modality that can induce complete, durable regression of certain human malignancies. Long-term follow-up of patients receiving tumor-infiltrating lymphocytes (TILs) for metastatic melanoma reveals a substantial subset that experienced complete, lasting tumor regression - and may be cured. Increasing evidence points to mutated gene products as the primary immunological targets of TILs from melanomas. Recent technological advances permit rapid identification of the neoepitopes resulting from these somatic gene mutations and of T cells with reactivity against these targets. Isolation and adoptive transfer of these T cells may improve TIL therapy for melanoma and permit its broader application to non-melanoma tumors. Extension of ACT to other malignancies may also be possible through antigen receptor gene engineering. Tumor regression has been observed following transfer of T cells engineered to express chimeric antigen receptors against CD19 in B-cell malignancies or a T-cell receptor against NY-ESO-1 in synovial cell sarcoma and melanoma. Herein, we review recent clinical trials of TILs and antigen receptor gene therapy for advanced cancers. We discuss lessons from this experience and consider how they might be applied to realize the full curative potential of ACT.
    Immunological Reviews 01/2014; 257(1):56-71. DOI:10.1111/imr.12132 · 10.12 Impact Factor
Show more